Header Logo

Connection

GAURI R VARADHACHARY to Biomarkers, Tumor

Back to Details
This is a "connection" page, showing publications GAURI R VARADHACHARY has written about Biomarkers, Tumor.
GAURI R VARADHACHARY
Connection Strength
1.046
Biomarkers, Tumor
  1. Carcinoma of Unknown Primary Site: The Poster Child for Personalized Medicine? JAMA Oncol. 2015 Apr; 1(1):19-21.
    View in: PubMed
    Score: 0.136
  2. Molecular profiling for CUP cancers: are we there yet? Onkologie. 2012; 35(1-2):11-2.
    View in: PubMed
    Score: 0.109
  3. Gene expression profiling in cancers of unknown primary. J Clin Oncol. 2009 Sep 01; 27(25):e85-6; author reply e87-8.
    View in: PubMed
    Score: 0.092
  4. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol. 2008 Jun; 9(6):596-9.
    View in: PubMed
    Score: 0.085
  5. Diagnostic strategies for unknown primary cancer. Cancer. 2004 May 01; 100(9):1776-85.
    View in: PubMed
    Score: 0.064
  6. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Clin Cancer Res. 2020 03 15; 26(6):1385-1394.
    View in: PubMed
    Score: 0.047
  7. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Gastroenterology. 2019 01; 156(1):108-118.e4.
    View in: PubMed
    Score: 0.043
  8. Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers. Radiology. 2017 05; 283(2):314-340.
    View in: PubMed
    Score: 0.039
  9. Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma. PLoS One. 2017; 12(2):e0171985.
    View in: PubMed
    Score: 0.039
  10. A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Support Care Cancer. 2017 06; 25(6):1809-1817.
    View in: PubMed
    Score: 0.039
  11. Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma. BMC Cancer. 2016 08 22; 16:668.
    View in: PubMed
    Score: 0.037
  12. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Ann Oncol. 2016 Apr; 27(4):635-41.
    View in: PubMed
    Score: 0.036
  13. Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. Hum Pathol. 2015 Sep; 46(9):1315-22.
    View in: PubMed
    Score: 0.034
  14. Cancer of unknown primary site. N Engl J Med. 2014 Aug 21; 371(8):757-65.
    View in: PubMed
    Score: 0.033
  15. Carcinoma of unknown primary: focused evaluation. J Natl Compr Canc Netw. 2011 Dec; 9(12):1406-12.
    View in: PubMed
    Score: 0.027
  16. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011 Aug 01; 29(22):3037-43.
    View in: PubMed
    Score: 0.026
  17. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer. 2010 Jul 14; 10:368.
    View in: PubMed
    Score: 0.025
  18. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol. 2008 Sep 20; 26(27):4442-8.
    View in: PubMed
    Score: 0.022
  19. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006 Aug; 13(8):1035-46.
    View in: PubMed
    Score: 0.019
  20. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 11; 11(11):2738-2747.
    View in: PubMed
    Score: 0.013
  21. Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer. Br J Cancer. 2021 06; 124(12):1970-1977.
    View in: PubMed
    Score: 0.013
  22. Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait. BMC Cancer. 2019 Oct 17; 19(1):965.
    View in: PubMed
    Score: 0.012
  23. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother. 2018 Jul/Aug; 41(6):284-291.
    View in: PubMed
    Score: 0.011
  24. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. Ann Oncol. 2018 01 01; 29(1):223-229.
    View in: PubMed
    Score: 0.010
  25. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
    View in: PubMed
    Score: 0.010
  26. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann Oncol. 2017 04 01; 28(4):741-747.
    View in: PubMed
    Score: 0.010
  27. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS One. 2016; 11(6):e0156910.
    View in: PubMed
    Score: 0.009
  28. Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma. Hum Pathol. 2014 May; 45(5):1015-23.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.